Agomelatine is an atypical antidepressant mainly prescribed for the treatment of major depressive disorder (MDD). It works by acting as an agonist at melatonin receptors (MT1 and MT2) and an antagonist at serotonin 5‑HT2C receptors, helping to restore circadian rhythm and improve mood regulation. Patients benefit from its ability to reduce depressive symptoms, improve sleep quality, and enhance daytime alertness without causing significant sexual dysfunction or weight gain, which are common with other antidepressants. Agomelatine is also studied for its potential in treating generalized anxiety disorder and bipolar depression, though its primary approved use remains in MDD.